Bladder – Bowel Institute Expands Provider Team to Include Urology, Now Offering Treatment for Male Patients

(Isstories Editorial):- Harrison, Arkansas Apr 23, 2024 (Issuewire.com) – In a substantial expansion of its healthcare services, Bladder & Bowel Institute (BBI) has added three new physicians in the past year to perform InterStim®, an FDA-approved minimally invasive procedure that provides relief for patients suffering from bladder or bowel control problems. Furthermore, two of the new physicians are urologists, allowing BBI to now offer advanced therapies for male patients.

Bladder & Bowel Institute has long been the world leader in treating female patients with bladder and bowel control problems but recognizing a similar need for advanced care in men, BBI is now ready to provide the same high level of care to male patients.

“Just like we see with women, men’s health, particularly in the areas of bladder and bowel control, has often not received the attention it deserves. By integrating services for men, we are filling this gap and offering new hope to many who have suffered in silence,” said BBI founder, Dr. Chris Taylor.

More on Isstories:

• SimpliDistance – Rise of the Specialist: Why Online MBAs with Focused Specializations are in Demand
• HireDynamicsDevelopers.com Announces the Entrance into the LATAM Market of Microsoft Dynamics Consultants
• Enhance Your Model Y Driving Experience with AceTesla.com’s Customized Accessories
• Corridor Coffee Club Launches Innovative Digital Coffee Passport Program
• Prominent Allergist-Immunologist James A. Thompson, MD, FACAAI, Revolutionizing Allergy Care in Greater Chicago

The new providers are Dr. Corey Smith, a gynecologist, and urologists Dr. Dan Decker and Dr. Austin Barber. They collectively bring a wealth of expertise and deep commitment to patient care that complements the care provided by Dr. Taylor, who was recently selected as a Medtronic Center of Excellence Distinguished Platinum Therapy Provider, a prestigious accolade acknowledging his impact on over 1,000 patient lives through the use of InterStim® therapy.

All three new physicians have extensive experience with InterStim®and have had successful private practices in North Central Arkansas for years.

Dr. Smith completed his undergraduate work at the University of Mississippi and medical school at St. George’s University School of Medicine, where he earned an MD/MPH dual degree. Following his time at St. George’s, he completed a residency in Obstetrics and Gynecology at Drexel University/Hahnemann University Hospital in Philadelphia. Dr. Smith is board-eligible through the American Board of Obstetrics and Gynecology and is a member of the American Medical Association, American College of Obstetrics and Gynecology, and Arkansas Medical Society.

Dr. Decker completed medical school at Wake Forest University School of Medicine and a residency in Urology at the University of Texas Southwestern Medical Center, one of the premier institutions in the country.

Dr. Barber completed his undergraduate work at the University of Georgia in Athens, medical school at Mercer University School of Medicine, and a general surgery internship and urology residency at the University of Arkansas for Medical Sciences. Dr. Barber also served as a Captain in the United States Air Force Reserve during his medical training.

Dr. Decker and Dr. Barber are board-certified by the American Board of Urology and are members of the American Medical Association, American Urological Association, and Arkansas Medical Society.

This expansion of the provider team and services strengthens BBI’s position as the world leader in treating patients with bladder and bowel control problems and their unwavering commitment to providing advanced care to the community.

For more information about Bladder & Bowel Institute, their team of providers, or their work with Medtronic InterStim®, please visit www.bladderbowelinstitute.com.

About Overactive Bladder

Overactive bladder (OAB) significantly impacts quality of life and can negatively affect social activities, and exercise and cause disruptive nighttime voiding.1,2 Many sufferers are frustrated and embarrassed and limit their lives socially, professionally, and personally.3 However, 45% don’t seek treatment and as many as seven in 10 stop using medications within six months due to intolerable side effects or unsatisfying results.4,5,6

Evidence points to OAB being caused by a miscommunication between the bladder and the brain.7 Sacral neuromodulation, or gentle stimulation of the sacral nerves, delivered by the InterStim® system is thought to normalize the brain-bladder communication pathway thereby restoring bladder function and alleviating symptoms. Restored function is defined as 50% reduction in dysfunctional voiding symptoms from baseline. The InterStim® system is the only sacral neuromodulation solution proven to demonstrate sustained five-year efficacy and quality-of-life improvements for OAB.8

About Fecal Incontinence

Fecal incontinence (FI) is a distressing and disruptive chronic condition that is characterized by the inability to control bowel movements, which results in frequent accidents and leakage. People with FI report more depression and embarrassment, as well as a lower quality of life compared to those without FI.9 Even though FI is treatable, 8.5 out of 10 adults haven’t even told their doctor about their FI.10 The InterStim® system is the only sacral neuromodulation solution proven to demonstrate sustained five-year efficacy and quality-of-life improvements for FI.11

About Medtronic® InterStim Therapy for Bladder and Bowel Control

Medtronic is the first and leading provider of neuromodulation solutions for bladder and bowel control issues. Sacral neuromodulation therapy delivered by the InterStim system was first approved twenty-five years ago and has helped more than 400,000 patients worldwide.

About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services, and solutions companies -alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

• Coyne, K. S., C. Payne, et al.. “The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey.” Value Health 2005;7(4): 455-463.
• Cartwright, R., S. Srikrishna, et al.. “Validity and reliability of patient selected goals as an outcome measure in overactive bladder.” Int Urogynecol J 2011;22(7): 841-847.
• Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Current Medical Research and Opinion. 2007;23:65-76
• Muller, N. “What Americans understand and how they are affected by bladder control problems: highlights of recent nationwide consumer research.” Urol Nurs 2005;25(2): 109-115.
• Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid Program. Value in Health. 2005;8(4)495-505.
• Leede Research, “Views on OAB: A Study for the National Association of Continence.” December 16, 2015.
• Leng WW, Morrisroe SN. Sacral nerve stimulation for the overactive bladder. Urol Clin N Am. 2006;33:491-501.
• Siegel, S., Noblett, K., Mangel J, et al. ” Five Year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated with Sacral Neuromodulation.” J Urol.2018;199(1), 229 – 236.
• Rockwood TH, Church JM, Fleshman JW, et al. Fecal Incontinence Quality of Life Scale – Quality of life instrument for patients with fecal incontinence. Dis Colon Rectum. 2000;43:9-16
• Damon H, Guye O, Seigneurin A, et al. Prevalence of anal incontinence in adults and impact on quality-of-life. Gastroenterol Clin Biol. 2006;30(1):37-43.
• Hull T, Giese C, Wexner SD, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56(2):23-245.

This article was originally published by IssueWire. Read the original article here.